Clinical Trial Update: Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of NBI-98854 for Tourette Syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-04-29